0000899243-22-034125.txt : 20221025 0000899243-22-034125.hdr.sgml : 20221025 20221025163101 ACCESSION NUMBER: 0000899243-22-034125 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221021 FILED AS OF DATE: 20221025 DATE AS OF CHANGE: 20221025 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Blaustein Marc CENTRAL INDEX KEY: 0001880032 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40227 FILM NUMBER: 221329851 MAIL ADDRESS: STREET 1: C/O FINCH THERAPEUTICS GROUP, INC. STREET 2: 200 INNER BELT ROAD, SUITE 400 CITY: SOMERVILLE STATE: MA ZIP: 02143 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Finch Therapeutics Group, Inc. CENTRAL INDEX KEY: 0001733257 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 823433558 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 INNER BELT ROAD CITY: SOMERVILLE STATE: MA ZIP: 02143 BUSINESS PHONE: 617-229-6499 MAIL ADDRESS: STREET 1: 200 INNER BELT ROAD CITY: SOMERVILLE STATE: MA ZIP: 02143 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-10-21 0 0001733257 Finch Therapeutics Group, Inc. FNCH 0001880032 Blaustein Marc C/O FINCH THERAPEUTICS GROUP, INC. 200 INNER BELT ROAD, SUITE 400 SOMERVILLE MA 02143 0 1 0 0 Chief Operating Officer Common Stock 2022-10-21 4 S 0 3636 1.39 D 32614 D Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Represents the weighted average price of shares sold by the broker on behalf of certain executive officers and employees of the company on October 21, 2022. The broker sold, in the aggregate on behalf of such employees, 21,137 shares in transactions ranging from $1.31 to $1.44 with a weighted average price of $1.39. The proceeds of all such sales were allocated to applicable employees on a pro rata basis based on the number of shares sold by such person. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. By: /s/ Joseph Vittiglio, Attorney-in-Fact 2022-10-25